Profile data is unavailable for this security.
About the company
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
- Revenue in USD (TTM)42.73m
- Net income in USD-204.38m
- Incorporated2012
- Employees317.00
- LocationWAVE Life Sciences Ltd7 Straits View#12-00, Marina One East Tower 018936SingaporeSGP
- Phone+65 62363388
- Websitehttps://www.wavelifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maze Therapeutics Inc | 0.00 | -101.46m | 2.13bn | 125.00 | -- | 5.60 | -- | -- | -2.68 | -2.68 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -41.05 | -- | -43.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 103.39 | -- | -- | -- |
| Grail Inc | 147.17m | -408.35m | 2.13bn | 1.00k | -- | 0.8254 | -- | 14.46 | -11.18 | -11.18 | 4.01 | 63.92 | 0.0498 | -- | 7.62 | -- | -13.83 | -- | -14.21 | -- | 48.46 | -- | -277.47 | -- | -- | -- | -- | -- | 17.18 | -- | 79.85 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 874.84m | 263.86m | 2.18bn | 435.00 | 7.22 | -- | 8.16 | 2.49 | 1.20 | 1.20 | 4.00 | -0.5593 | 1.74 | 2.83 | 9.41 | 2,011,120.00 | 52.53 | -18.78 | 81.42 | -25.41 | 97.82 | 97.60 | 30.16 | -23.15 | 2.03 | 4.99 | 1.34 | -- | 94.10 | 117.89 | 396.87 | -- | 36.86 | -- |
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.26bn | 51.00 | -- | 3.91 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -446.21m | 2.36bn | 258.00 | -- | 2.48 | -- | -- | -3.54 | -3.54 | 0.00 | 5.89 | 0.00 | -- | -- | 0.00 | -47.52 | -55.84 | -49.99 | -60.48 | -- | -- | -- | -- | -- | -- | 0.1328 | -- | -- | -- | -40.58 | -- | 77.94 | -- |
| Dianthus Therapeutics Inc | 3.08m | -126.35m | 2.37bn | 78.00 | -- | 4.34 | -- | 771.57 | -3.48 | -3.48 | 0.085 | 12.75 | 0.0066 | -- | 0.8013 | 39,461.54 | -27.12 | -37.13 | -28.32 | -39.78 | -- | -- | -4,104.78 | -3,874.39 | -- | -- | 0.00 | -- | 120.63 | -- | -95.08 | -- | -49.06 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.38bn | 118.00 | -- | 7.48 | -- | 245.54 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Disc Medicine Inc | 0.00 | -212.18m | 2.46bn | 155.00 | -- | 3.30 | -- | -- | -5.98 | -5.98 | 0.00 | 19.53 | 0.00 | -- | -- | 0.00 | -32.55 | -30.94 | -34.12 | -32.93 | -- | -- | -- | -- | -- | -- | 0.0379 | -- | -- | -- | -94.03 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.48bn | 624.00 | -- | 11.30 | -- | 8.94 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | 443,871.80 | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -30.92 | -- |
| Wave Life Sciences Ltd | 42.73m | -204.38m | 2.53bn | 317.00 | -- | 4.87 | -- | 59.22 | -1.21 | -1.21 | 0.2534 | 2.80 | 0.0863 | -- | 31.67 | 134,785.50 | -41.26 | -44.67 | -52.09 | -71.58 | -- | -- | -478.33 | -208.12 | -- | -- | 0.00 | -- | -60.55 | 16.31 | -110.68 | -- | -11.71 | -- |
| Travere Therapeutics Inc | 490.73m | -50.26m | 2.61bn | 497.00 | -- | 22.38 | 248.78 | 5.31 | -0.603 | -0.3293 | 5.30 | 1.26 | 0.8184 | 1.71 | 9.15 | 987,382.30 | -8.38 | -37.69 | -11.99 | -48.59 | 97.89 | 96.60 | -10.24 | -116.71 | 2.70 | -- | 0.7308 | -- | 110.45 | 19.87 | 84.32 | -- | 18.81 | -- |
| Beam Therapeutics Inc | 139.74m | -79.99m | 2.77bn | 511.00 | -- | 2.24 | -- | 19.84 | -0.9703 | -0.9703 | 1.41 | 12.17 | 0.1081 | -- | -- | 273,469.70 | -6.19 | -19.28 | -6.94 | -22.57 | -- | -- | -57.24 | -176.36 | -- | -- | 0.00 | -- | 120.01 | 466.27 | 78.77 | -- | -1.79 | -- |
| Veracyte Inc | 517.15m | 66.35m | 2.79bn | 755.00 | 43.06 | 2.13 | 31.76 | 5.39 | 0.8147 | 0.8147 | 6.45 | 16.50 | 0.3822 | 7.31 | 11.34 | 684,960.30 | 4.90 | -1.69 | 5.17 | -1.78 | 70.10 | 67.87 | 12.83 | -5.22 | 7.81 | -- | 0.00 | -- | 16.01 | 34.50 | 174.89 | -- | 27.81 | -- |
| Vera Therapeutics Inc | 0.00 | -299.62m | 2.80bn | 249.00 | -- | 4.63 | -- | -- | -4.66 | -4.66 | 0.00 | 8.48 | 0.00 | -- | -- | 0.00 | -43.10 | -46.45 | -45.69 | -50.25 | -- | -- | -- | -- | -- | -- | 0.1102 | -- | -- | -- | -96.92 | -- | 44.79 | -- |
| Arcus Biosciences Inc | 247.00m | -353.00m | 2.81bn | 601.00 | -- | 4.45 | -- | 11.38 | -3.30 | -3.30 | 2.30 | 5.04 | 0.2158 | -- | 12.05 | 410,981.70 | -30.84 | -18.85 | -38.54 | -22.29 | -- | -- | -142.92 | -103.61 | -- | -- | 0.1356 | -- | -4.26 | 26.08 | -24.73 | -- | -8.12 | -- |
Data as of Mar 03 2026. Currency figures normalised to WAVE Life Sciences Ltd's reporting currency: US Dollar USD
50.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2025 | 18.20m | 9.95% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 13.65m | 7.46% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 10.02m | 5.47% |
| Adage Capital Management LPas of 31 Dec 2025 | 9.79m | 5.35% |
| Maverick Capital Ltd.as of 31 Dec 2025 | 9.28m | 5.07% |
| Darwin Global Management Ltd.as of 31 Dec 2025 | 7.30m | 3.99% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 7.26m | 3.97% |
| Driehaus Capital Management LLCas of 31 Dec 2025 | 6.58m | 3.60% |
| M28 Capital Management LPas of 31 Dec 2025 | 5.66m | 3.10% |
| Federated Global Investment Management Corp.as of 31 Dec 2025 | 4.74m | 2.59% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
